ABSTRACT
INTRODUCTION
Chemotherapy treatment in cancer has long been associated with development of systemic immune suppression (1, 2) (4)). Until recently, the mechanisms by which chemotherapy treatment facilitated an adaptive, tumor-specific immune response were largely uncharacterised. Certain alarmins or danger-associated molecular patterns (DAMPs) are expressed or released during tumor cell death induced by immunogenic chemotherapeutic agents, including anthracyclines. These include translocation of the endoplasmic reticulum resident calreticulin complex to the plasma membrane, providing an 'eatme' signal (5-7) and release of the nuclear alarmin HMGB1 to engage TLR-4 on dendritic cells (DC) (8, 9) . In addition, we showed recently that dying tumor cells release ATP, which then acts on P2X7 purinergic receptors from DCs and triggers the NOD-like receptor family, pyrin domain containing-3 protein (NLRP3)-dependent caspase-1 activation complex ('inflammasome'), allowing for the secretion of pro-inflammatory IL-1β. Accordingly, anticancer chemotherapy turned out to be inefficient against tumors established in purinergic receptor P2rx7-or Nlrp3-or Author Manuscript Published OnlineFirst on June 6, 2011; DOI: 10.1158/0008-5472. Anthracyclines have been used in anti-cancer treatment for more than 40 years and now have a major role in the management of leukaemia, lymphoma, uterine, ovarian, sarcoma and breast malignancies. Doxorubicin became the most widely used anthracycline because of lower toxicity and potent anti-tumor activity against solid tumors. Although there were earlier reports evidencing the immune system contribution to doxorubicin-mediated anti-tumor effects (11, 12) , Maccubbin et al. 1990 , was the first to show that doxorubicin was an effective immunomodulator capable of boosting cytotoxic T lymphocyte (CTL) responses (13) . A multitude of studies investigating combination treatment of doxorubicin and immune therapies followed, however the underlying mechanisms of how immunogenic cell death caused by doxorubicin links to induction of a cytotoxic CD8 T cell response was largely unknown.
Using experimental and carcinogen-induced mouse models of breast cancer and fibrosarcoma,
respectively, here we demonstrate key cytokines and immune cell populations required for the anti-tumor therapeutic efficacy of doxorubicin. We show that CD8 T cells and IFN-γ are critical effectors of IL-1β-and IL-17-dependent signaling in response to doxorubicin treated breast tumors and sarcomas and corroborating this we also report that CD8α, CD8β and IFN-γ gene expression levels in breast cancer patients treated with anthracycline chemotherapy correlate with treatment response. Mice 6-14 weeks of age were used in all experiments and all procedures were approved by the Peter Mac Animal Ethics Committee.
Tumor Models
Experimental. C57BL/6-derived AT3 (kindly provided by Trina Stewart, Peter Mac) and E0771 (16) , and BALB/c-derived H2N100 mammary adenocarcinoma (17) 
In vivo CD8 T cell assays and flow cytometry
OT-I T cells were purified from spleens and lymph nodes of OT-I transgenic mice, with positive selection using a CD8 T cell isolation kit (Miltenyi Biotec, North Ryde, Australia). CD8 T cell purity was always found to be greater than 90%. Purified OT-I cells were labeled with 2. 
Gene expression analysis
Two cohorts of breast cancer gene expression datasets were used for these analyses. Complete clinical data is included in the supplementary information (Supp Table 1 21 . When multiple probes were mapped to the same GeneID, the one with the highest variance in a particular dataset was selected to represent the GeneID. Each gene analysed was then scaled such that quartiles 2.5% and 97.5% are equal to -1 and +1 respectively. This scaling is robust to outliers and hence allows combination of the microarray data from each dataset. This meta-analytical technique has been previously described (24) (25) (26) . Univariate Cox regression analysis was used to determine prognostic significance with clinical outcome of the genes as a continuous measurement and were calculated stratified by dataset.
The second cohort of breast cancer patients was treated with anthracycline chemotherapy to determine the association of immune genes with clinical response to doxorubicin. These women compared with doxorubicin. Tumor biopsies were taken using a core biopsy 14-16 G needle prior to chemotherapy. Clinical endpoint used was pathological complete response (pCR) documented at surgery, which is an accepted surrogate for disease-free and overall survival in breast cancer. Genes were correlated with pCR as a continuous variable (i.e. to determine if higher expression correlated with a higher chance of obtained pCR) using a receiver operating characteristic (ROC) and measured using an area under the curve (AUC). Microarray analysis was performed using Affymetrix GeneChips.
Statistical analysis
Mouse. Statistical analyses were performed using GraphPad Prism software (La Jolla, CA). Significant differences between groups were assessed by a two-tailed t test or MannWhitney U test, as indicated. Values of P < 0.05 were considered significant. Fig. 2A, Supplementary Fig. 4 ). This variable response was consistent with the vast heterogeneity between individual MCA-induced fibrosarcomas. Importantly, the significant therapeutic effect of doxorubicin in inhibiting fibrosarcoma growth across the whole cohort of control mAb-treated mice (p <0.0001) ( Supplementary Fig. 4 ) was abolished if mice received anti-CD8α mAb or anti-IFN-γ mAb during doxorubicin therapy (Fig. 2B,C; Supplementary Fig 4) , indicating that both CD8 + T cells and IFN-γ were critical for the anti-tumor effects of doxorubicin.
Doxorubicin treatment enhances antigen-specific CD8 T cell proliferation in vivo.
We next investigated in more detail the antigen-driven responses of CD8 T cells following chemotherapy in breast cancer. Immunocompetent B6 mice showed considerable resistance to challenge with subcutaneous AT3 (Fig. 3A) . Furthermore, in vivo proliferation of OT-I cells in the presence of OVA, as measured by CFSE dilution, was significantly increased after doxorubicin treatment (Fig. 3B) .
Overall, localized doxorubicin treatment of established tumors enhances the accumulation and proliferation of CD8 T cells responding to cognate tumor antigen in secondary lymphoid organs. (Fig. 4A) , and a similar increase was observed for infiltrating Ag-specific OT-I cells (Fig. 4B) . Doxorubicin treatment also induced Ag-specific IFN-γ production from CD8 TILs, observed after in vitro re-stimulation with cognate antigen (Fig. 4C) 
Doxorubicin treatment requires IL-1β and IL-17, but not IL-23p19
We have recently demonstrated that IL-1β production is pivotal for a robust anti-tumor response to chemotherapy, by facilitating the priming of tumor-specific CD8 T cells (10) . We now have extended these findings in a range of mammary adenocarcinomas to show that IL-1β/IL-1R signaling is also critical to the therapeutic outcome of doxorubicin treatment (Fig. 5) . Since IL-1β is known to regulate IL-17 responses (35-37), we utilized both IL-17A -/-mice and an anti-IL-17Rα mAb, to also demonstrate a critical role for IL-17 in doxorubicin treatment of transplantable mammary tumors (Fig. 5) . In concert with the mammary carcinoma data, a 
critical role for IL-1β and IL-17A in doxorubicin anti-tumor activity was also illustrated using fibrosarcomas generated de novo by MCA ( Fig. 6B; Fig. 6D; Supplementary Fig 4) . Fig. 6C; Supplementary Figs. 2 and 4 ). In addition, by comparison the anti-tumor efficacy of doxorubicin in transplanted tumors was partially reduced in the absence of the IL-12p35 subunit ( Supplementary Fig. 2 ).
Doxorubicin therapy requires γδ T cells, but not type I NKT cells.
Both NKT cells and γδ T cells have been implicated in innate immune surveillance of tumors (38, 39) and are also a potent early source of IL-17 in response to IL-1β cytokine stimulation (35, 36) . We assessed the requirement for these innate lymphocytes in doxorubicin therapy of established AT3 mammary tumors and MCA205 fibrosarcomas (Supplementary Fig. 3 Clinical relevance using gene expression data from human breast cancer patients.
We went on to explore if these genes were important for therapeutic efficacy of anthracycline treatment in breast cancer patients using publicly available gene expression datasets. The first cohort consisted of patients diagnosed at multiple different hospitals who had their tumor biopsies taken at surgery. The samples examined here are representative of the global breast cancer population as there was a mixture of different tumor sizes, nodal status and estrogen receptor (ER) expression (Supplementary Table 1 ). As these women received no systemic treatment, the true prognostic effects of these genes could be examined without treatment confounders. Therefore, we could examine the prognostic significance of CD8A, CD8B, IFNγ, IL1B, IL17A and IL23p19 genes independent of anthracycline therapy in patients who had received no systemic treatment (19-22) ( Table 1) . As observed, only high IFN-γ levels were associated with a good prognosis in these women -i.e. high levels were associated with fewer long-term breast cancer relapses.
We then went on to examine these genes in the context of treatment with anthracycline chemotherapy. The second cohort consisted of women enrolled into a breast cancer clinical trial specifically designed to investigate biomarkers to anthracycline chemotherapy. As a consequence, all of the women in this study were negative for expression of ER (as this is the more chemo-responsive breast cancer population) and all received single agent epirubicin, an anthracycline type chemotherapy commonly used in clinical practise. Tumor biopsies were taken with core biopsy needles and were subject to gene expression profiling prior to chemotherapy (27) . In these breast cancer patients increasing levels of IFN-γ, and also CD8α and CD8β were In human breast cancer patients, whilst IFN-γ levels seemed relevant for patient clinical outcome independent of anthracycline, the importance of both CD8 T cells and IFN-γ in therapeutic efficacy was supported by the observation that increasing levels of CD8α, CD8β and IFN-γ gene expression correlated with a better response to anthracycline chemotherapy. Notably, here the tumor biopsies were taken prior to chemotherapy, supporting the concept that an intact immune system aids therapeutic response to anthracyclines. However, it would be most interesting to also see the relative changes in gene expression before and shortly after administration of therapy.
Whilst the analyses in human breast cancer patients presented here are limited by the use of retrospective datasets, non-randomized treatment cohorts and patients treated with epirubicin rather than doxorubicin, which is a different type of anthracycline chemotherapy, it supports our 
causal relationship of IL-1β production from APC causing IL-17 production from γδ T cells, and resulting in IFN-γ production from tumor-specific CD8 T cells. The current study provides important additional data in mammary tumor transplant and de novo fibrosarcoma models to support a role for IL-17A in doxorubicin mechanism of action. In doing so, we also demonstrate the relevance of γδ+ T cells, but not type I NKT cells.
Overall, our in vivo mouse data and human genetic analysis demonstrates the role of host CD8 T cells and IFN-γ in doxorubicin mechanism of action. The study also strongly supports our most recent work on the role of IL-17A in the mechanism of action of chemotherapy (41) distant metastases. Cohort 2 consisted of 114 patients treated in a neoadjuvant trial of the anthracycline epirubicin given as a sole therapy prior to surgery. All patients were ER-negative with 86% of tumors >2cm and 54% with positive lymph nodes at study entry. Biopsies were taken prior to therapy. Here, increasing expression of IFN-γ, CD8A and CD8B are associated with a higher chance of a complete response from chemotherapy at surgery. In this second cohort, a pCR was strongly correlated with a better survival from breast cancer. (Full clinical information for cohorts 1 and 2 can be found in the Supplementary Table 1) .
CI: confidence interval pCR: pathological complete response: complete disappearance of invasive tumor at surgery after 4 cycles of epirubicin chemotherapy given at 100 mg/m 2 .
